Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex-deficient cancers

Mariko Sasaki1,2 | Hideaki Ogiwara1

1Division of Cancer Therapeutics, National Cancer Center Research Institute, Tokyo, Japan
2Molecular Oncology, Jikei University Graduate School of Medicine, Tokyo, Japan

Correspondence
Hideaki Ogiwara, Division of Cancer Therapeutics, National Cancer Center Research Institute, Tokyo, Japan. Email: hogiwara@ncc.go.jp

Abstract
The SWI/SNF chromatin remodeling complex is composed of approximately 15 subunits, and approximately 20% of all cancers carry mutations in the genes encoding these subunits. Most of the genetic alterations in these genes are loss-of-function mutations. The identification of vulnerability based on synthetic lethality in cancers with SWI/SNF chromatin remodeling complex deficiency contributes to precision medicine. The SWI/SNF chromatin remodeling complex is involved in transcription, DNA repair, DNA replication, and chromosomal segregation. Cancers with deficiency in the SWI/SNF chromatin remodeling complex show increased vulnerability derived from the loss of these functions. Synthetic lethal targets have been identified based on vulnerabilities in the functions of the SWI/SNF chromatin remodeling complex. In this review article, we propose a precision medicine strategy using chemotherapeutic methods, such as molecular targeted therapy and immunotherapy, based on harnessing synthetic lethality in cancers with deficiency in the SWI/SNF chromatin remodeling complex.

KEYWORDS
chromatin remodeling, epigenetics, molecular targeted therapy, precision medicine, synthetic lethality

1 | THERAPEUTIC STRATEGY BASED ON SYNTHETIC LETHALITY FOR LOSS-OF-FUNCTION MUTATED CANCERS

Current precision medicine strategies for human cancers target activated proteins such as the tyrosine kinases EGFR, BRAF, and ALK-fusion; these proteins are activated by gain-of-function genetic aberrations including gene mutation, amplification, and fusion (Figure 1).1-3 Activated oncogenes constitute a specific vulnerability of cancer cells. Inhibition of the synthesis or activity of these oncogenes results in cell death, specifically in cells expressing the activated oncogene; the dependence of cells on an oncogene for survival is defined as "oncogene addiction".4 Only a fraction of cancers have an activated oncogene, whereas many cancers have other genetic aberrations such as loss-of-function (LOF) mutations. Certain LOF gene mutations of tumor suppressor genes confer druggable vulnerabilities on cancer cells. However, because genes with LOF mutations are inactivated, the LOF mutation gene product is not a target for inhibition (Figure 1). Harnessing synthetic lethality, such as that based on LOF gene mutations, has emerged as an attractive therapeutic strategy; however, to date, this strategy has not been widely successful. Synthetic lethality is defined by an interdependent relationship between 2 genes, which means that simultaneous loss of 2 genes, but not loss of either gene alone, leads to cell death (Figure 1).5-7 Cancer cells harboring a LOF gene mutation would therefore be vulnerable to inhibition of the synthetic lethal target.
“Cancer” with GOF mutation → targeting mutated protein!

Normal cells  Cancer cells

A  B
Life ?  Death

a: EGFR  Gefitinib  Lung

a: BRAF  Vemurafenib  Skin

a: ALK-fusion  Crizotinib  Lung

“Cancer” with LOF mutation → targeting synthetic lethal protein!

Normal cells  Cancer cells

A  B
Life  Death

a: BRCA1/BRCA2  Synthetic lethal  Ovarian/Breast

B: PARP1  Olaparib

Synthetic Lethality

Life  Life  Death

FIGURE 1  Precision medicine based on cancer mutations. PARP, poly(ADP-ribose) polymerase

FIGURE 2  Synthetic lethal therapy: cancer therapy based on synthetic lethality

In this review, “synthetic lethal therapy” is defined as cancer therapy based on synthetic lethality. This strategy is based on the assumption that a cancer patient has a LOF mutation of “gene A” and gene A is synthetic lethal with gene B (Figure 2). In cancer cells, gene A is the LOF gene, and therapy with an inhibitor of B causes cell death based on synthetic lethality because of the simultaneous suppression of the function of both A and B. In normal cells, gene A is normal; therefore, inhibition of gene B does not affect the survival of normal cells. Synthetic lethal therapy is expected to have high selectivity against cancer cells and few side-effects. Thus, the identification of cancer vulnerabilities associated with LOF gene mutations should lead to marked improvements in cancer therapy, as epitomized by the success of poly(ADP-ribose) polymerase (PARP)1-targeted therapy against hereditary breast and ovarian cancers harboring LOF mutations of the BRCA1 and BRCA2 genes.8,9

2  |  ROLE OF CHROMATIN REGULATING FACTORS

Chromatin regulating factors are largely divided into 2 groups: chromatin remodeling complexes and histone modifying factors (Figure 3). Chromatin remodeling complexes use the energy of ATP hydrolysis and maintain chromatin structure by opening or closing chromatin through sliding, ejecting, repositioning, or inserting nucleosomes, which are histone octamers composed of histones H2A, H2B, H3, and H4.10 Histone modifying factors maintain the
interaction between DNA and histones through histone methylation/demethylation, acetylation/deacetylation, and ubiquitylation/deubiquitylation. These chromatin regulating factors control binding of various functional proteins, such as transcription factors, DNA replication factors, DNA repair factors, and chromosome segregation factors to chromatin by remodeling and modifying chromatin structure. Therefore, chromatin regulating factors contribute to the regulation of transcription, DNA repair, DNA replication, and chromosomal segregation.

3 | GENETIC ABNORMALITY OF SWI/SNF CHROMATIN REMODELING GENES IN VARIOUS CANCERS

Recent advances in genome-wide sequencing technologies have contributed to the identification of most gene mutations associated with cancer. Comprehensive genome studies identified mutations in genes involved in chromatin regulation in approximately 50% of cancers. Most of the mutations in chromatin regulating genes are LOF mutations such as deleterious missense mutations, frameshift mutations, and chromosomal deletions. Mutations in SWI/SNF chromatin remodeling genes occur with high frequency in cancer; they are detected in approximately 20% of all cancer patients. The SWI/SNF chromatin remodeling complex relies on the catalytic activities of the SWI/SNF2-like ATPase and helicase domains. It is composed of accessory subunits harboring chromatin-binding motifs, such as a bromodomain. Specifically, LOF genetic aberrations of SMARCA4, ARID1A, ARID2, PBRM1, and SMARCB1 are common in various cancers such as lung cancer, ovarian clear cell carcinoma, skin cancer, renal clear cell carcinoma, and rhabdoid tumors, respectively. Gain-of-function genetic aberrations of SS18 by fusion of SS18 and SSXs (SSX1, SSX2, or SSX4) are observed in all synovial sarcoma patients. Most SWI/SNF chromatin remodeling genes, except the SS18-SSX fusion, cause LOF genetic aberrations in cancer. Therefore, the development of therapies based on synthetic lethality would be a promising therapeutic strategy. In this review, we introduce a synthetic lethal therapy strategy for the treatment of cancers with genetic aberrations of SWI/SNF chromatin remodeling genes (Figures 4 and 5).

4 | SYNTHETIC LETHAL TARGETS BASED ON TARGETING THE INTERACTION BETWEEN 2 SUBUNITS IN THE SWI/SNF CHROMATIN REMODELING COMPLEX

The SWI/SNF chromatin remodeling complex is a large complex composed of many different subunits, including functional subunits, such as catalytic, structural, and DNA binding subunits. Therefore, cancers deficient in the SWI/SNF chromatin remodeling complex are vulnerable because the interactions between subunits can be targeted for inactivation (Figure 5A). SMARCA4 and its paralog SMARCA2 have an ATPase domain that supplies
energy for chromatin remodeling activity. Therefore, the ATPase function of the SWI/SNF chromatin remodeling complex requires either SMARCA4 or SMARCA2. According to the mutually exclusive paralogs SMARCA4 and SMARCA2, the SWI/SNF chromatin remodeling complex exists as a SMARCA4-containing complex or a SMARCA2-containing complex. Therefore, loss of SMARCA4 or SMARCA2 leads to functional deficiency of the SMARCA4-containing complex or SMARCA2-containing complex, respectively. Work from our group showed that SMARCA4-deficient lung adenocarcinoma cells are sensitive to siRNA-mediated suppression of SMARCA2.\textsuperscript{20} This was supported by follow-up studies.\textsuperscript{21,22} Conversely, SMARCA2-deficient esophageal squamous carcinoma

**FIGURE 4** Genetic abnormality of SWI/SNF chromatin remodeling components in various cancers

**FIGURE 5** Synthetic lethal targets in cancers deficient in the SWI/SNF chromatin remodeling complex. A, Synthetic lethal targets based on targeting the interaction between 2 subunits in the SWI/SNF chromatin remodeling complex. B, Synthetic lethal targets based on targeting the competitor with the SWI/SNF chromatin remodeling complex. C, Synthetic lethal targets based on targeting the function of the SWI/SNF chromatin remodeling complex.
cells are sensitive to inhibition of SMARCA4.23 These observations suggest that the genetic relationship between SMARCA4 and SMARCA2 is a synthetic lethal relationship. The development of SMARCA4 and SMARCA2 inhibitors would be promising as a synthetic lethal therapy strategy for SMARCA4-deficient cancers and SMARCA4-deficient cancers, respectively. SMARCA2 and SMARCA4 proteins are potential druggable targets because they possess ATPase and bromo domains. The development of inhibitors of SMARCA4 and SMARCA2 based on protein degradation could provide promising therapeutic opportunities (WO2016138114; Genentech and Constellation).

Similar to the synthetic lethal relationship between the SMARCA4 and SMARCA2 paralogous pairs, ARID1A and its paralog ARID1B form a synthetic lethal pair. ARID1A and ARID1B are mutually exclusive components of the BAF complex. ARID1A-deficient ovarian clear cell carcinoma cells are sensitive to siRNA-mediated suppression of ARID1B. Loss of both ARID1A and ARID1B causes collapse of the BAF complex and leads to loss of functional activity of the BAF complex.24 Therefore, inhibition of ARID1B function is a promising strategy for ARID1A-deficient cancers. However, because ARID1B does not contain functional domains, such as a catalytic domain that could serve as a target for drug development, it would be difficult to develop an inhibitor against ARID1B. A modified approach to the inhibition of ARID1B may be the use of BRD2 inhibitors because inhibition of BRD2 represses the transcriptional expression of ARID1B. In fact, ARID1A-deficient cancer cells are more sensitive to BRD2 inhibitors than ARID1A-proficient cancer cells.25 Therefore, BRD2 inhibitors would be promising for the treatment of ARID1A-deficient cancers because of induction of synthetic lethality through suppression of ARID1B.

SMARCB1 and SS18 are components of the BAF complex. SMARCB1 is genetically aberrant because of LOF gene mutation or chromosomal deletion in pediatric and juvenile cancers such as rhabdoid tumor and epithelioid sarcoma.26,27 SS18 is genetically aberrant because of fusion with SSXs (SSX1, SSX2, or SSX4) in synovial sarcoma. The SS18-SSX fusion protein is incorporated into the BAF complex, resulting in loss of the SMARCB1 protein from the BAF complex.19,28 This suggests that the BAF complex containing the SS18-SSX fusion protein is deficient in SMARCB1 function. SMARCB1-deficient cancer cells and SS18-SSX fusion cancer cells are synthetic lethal because of inhibition of a subunit of the ncbAF complex, such as BRD9.18,29,30 Thus, BAF complex-deficient cancers, such as SMARCB1-deficient cancers, depend on the function of the residual ncbAF complex. A BRD9 inhibitor would therefore be a promising strategy for SMARCB1-deficient cancers.

Comprehensive analysis of synthetic lethality between 2 factors in all subunits of the SWI/SNF chromatin remodeling complex showed that the SMARCA4-ARID2, SMARCA4-ACTB, and SMARCC1-SMARCC2 pairs are significant for synthetic lethality.21 Considering synthetic lethality among these pairs, the SMARCA4 and ARID2 relationship would be a potential target for synthetic lethal therapy because SMARCA4 and ARID2 are frequently mutated in cancer.

5 | SYNTHETIC LETHAL TARGETS BASED ON TARGETING THE COMPETITOR WITH THE SWI/SNF CHROMATIN REMODELING COMPLEX

Transcription is regulated by the balance between the promotion and repression of gene expression by various chromatin regulatory factors. Therefore, cancers deficient in the SWI/SNF chromatin remodeling complex are vulnerable because of the abrogation of transcriptional balance (Figure 5B). The SWI/SNF chromatin remodeling complex promotes gene expression by inducing chromatin relaxation at the promoter and enhancer regions. In contrast, polycomb repressive complex 2 (PRC2), which is composed of the polycomb repressive complex 2 (PRC2), which is composed of the methyltransferase EZH2 and the noncatalytic regulatory subunits SUZ12 and EED, represses gene expression by promoting chromatin compaction through histone H3 K27 trimethylation (H3K27me3) at the promoter and enhancer regions. The SWI/SNF chromatin remodeling complex and PRC2 thus interact in a competitive manner to promote and repress transcription.32,33 In cancer cells deficient in SMARCA4, SMARCB1, ARID1A, and PBRM1 of the SWI/SNF chromatin remodeling complex, inhibition of EZH2 causes synthetic lethality.32,34-36 This competitive relationship suggests that deficiency in the SWI/SNF chromatin remodeling complex promotes PRC2 activity through loss of the complex’s restraint; cancer cells deficient in SWI/SNF chromatin remodeling complex thus depend on PRC2 activity.37,38 An inhibitor of EZH2 would be promising for SWI/SNF chromatin remodeling complex-deficient cancers. Several EZH2 inhibitors have been developed by various companies. The EZH2 inhibitor tazemetostat is currently in clinical trials39; it has shown limited clinical activity in SMARCB1-deficient epithelioid sarcoma (NCT02601950).

Although the SWI/SNF chromatin remodeling complex promotes the transcription of many genes, it also represses the transcription of certain genes. The histone deacetylase HDAC6 gene is repressed by the SWI/SNF chromatin remodeling complex. ARID1A deficiency upregulates HDAC6 expression through derepression caused by deficiency in the SWI/SNF chromatin remodeling complex. ARID1A-deficient cancers depend on the activation of HDAC6, and inhibition of HDAC6 causes synthetic lethality in ARID1A-deficient cancers.40 The HDAC6 inhibitors would be promising agents for the treatment of ARID1A-deficient cancers.

6 | SYNTHETIC LETHAL TARGETS BASED ON TARGETING THE FUNCTION OF THE SWI/SNF CHROMATIN REMODELING COMPLEX

The SWI/SNF chromatin remodeling complex functions in transcription, DNA repair, DNA replication, and chromosomal segregation. Therefore, cancers deficient in the SWI/SNF chromatin remodeling complex are vulnerable because of the abrogation of these cellular
functions (Figure 5C). Regarding DNA repair, the SWI/SNF chromatin remodeling complex is involved in DNA double-strand break repair and DNA damage checkpoint regulation. The PARP1 inhibitor olaparib is approved for BRCA1/2-deficient ovarian and breast cancers, which are deficient in homologous recombination repair, a DNA double-strand break repair mechanism. In ARID1A-deficient cancers, which are deficient in homologous recombination-mediated DNA double-strand break repair, treatment with a PARP inhibitor causes synthetic lethality.31

In the SWI/SNF chromatin remodeling complex, the BAF complex is required for chromatin binding of topoisomerase II (TOP2), which is necessary for DNA replication and chromosomal segregation. ARID1A mediates the physical interaction between the BAF complex and TOP2.42 Thus, TOP2 dysfunction in BAF complex-deficient tumors, such as ARID1A-deficient cancers, results in aberrant DNA replication and chromosomal segregation. Based on the abnormality of those cellular functions, BAF complex-deficient cancer cells are selectively sensitive to inhibitors of the cell cycle regulators cyclin-dependent kinase (CDK)4/CDK6, the DNA replication checkpoint factor ATR, and the chromosomal segregation factor Aurora kinase A.43–47

The SWI/SNF chromatin remodeling complex is involved in the regulation of several metabolic pathways. The energy supply in cancer cells is derived from ATP generated by the glycolytic pathway. However, SMARCA4-deficient lung cancer cells depend on energy supplied by the oxidative phosphorylation pathway rather than the glycolytic pathway, and are therefore sensitive to inhibition of oxidative phosphorylation.48 In addition, the cells are exposed to oxidative stress, such as that caused by reactive oxygen species (ROS), which damage DNA and proteins. Excessive generation of ROS leads to induction of cell death. However, the intracellular antioxidant system can effectively mediate resistance to oxidative stress by suppressing ROS through the antioxidant metabolite glutathione (GSH). Thus, the balance between oxidative stress and the antioxidant metabolite GSH maintains cellular homeostasis. We recently showed that impairment of the GSH metabolic pathway is a vulnerability of ARID1A-deficient cancer cells.49 Glutathione is a tripeptide metabolite synthesized from cysteine, glutamate, and glycine. ARID1A positively regulates the transcription of SLC7A11, which encodes a protein required for the maintenance of intracellular cysteine.49 Deficiency in ARID1A results in SLC7A11 downregulation, which decreases intracellular cysteine. The low basal level of GSH in ARID1A-deficient cancer cells leads to vulnerability. Inhibition of GSH by the GSH inhibitor APR-246 or buthionine sulfoximine, an inhibitor of the glutamate cysteine ligase catalytic subunit (which catalyzes the synthesis of GSH), causes excessive increase of ROS and leads to synthetic lethality in ARID1A-deficient cancer cells.49 These data indicate that inhibitors of metabolic pathways, such as the oxidative phosphorylation pathway and the GSH metabolic pathway, are promising therapeutic agents for cancers with deficiencies in the SWI/SNF chromatin remodeling complex because of vulnerabilities derived from metabolic pathway deficiencies.

ARID1A and PBRM1 are components of different complexes, namely, the BAF complex and PBAF complex, respectively. Therefore, immunotherapies against ARID1A-deficient cancers and PBRM1-deficient cancers should be based on different mechanisms. Cancers with a genetic aberration in mismatch repair are characterized by hypermutation frequency and should respond to immune checkpoint inhibition using programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) Abs because of increased antigen presentation.50 The ARID1A-containing BAF complex interacts with mismatch repair factors and positively regulates mismatch repair. Therefore, ARID1A-deficient cancer cells have a high mutation rate because of the deficiency in mismatch repair.51 Cancer immunotherapy would be a promising strategy for ARID1A-deficient cancers. In addition to mismatch repair deficiency, the activity of the interferon-γ signaling pathway modulates the sensitivity to cancer immunotherapy.52 The PBRM1-containing PBAF complex functions in the repression of genes involved in promoting interferon-γ signaling pathway activity.53 PBRM1-deficient renal clear cell carcinoma would benefit from cancer immunotherapy because the interferon-γ signaling pathway is activated in PBRM1-deficient cancer cells. Cancer immunotherapy is a promising strategy for cancers deficient in the SWI/SNF chromatin remodeling complex.

The effect of SWI/SNF chromatin remodeling complex deficiency on the response to chemotherapy using cytotoxic anticancer agents remains unclear. Ovarian clear cell carcinoma has the highest rate of ARID1A mutation among cancers. ARID1A-deficient ovarian clear cell carcinoma cells are selectively sensitive only to gemcitabine among the standard chemotherapeutic agents for ovarian clear cell carcinoma that are currently available.54 The first-line standard chemotherapy for ovarian clear cell carcinoma is combination therapy with paclitaxel and carboplatin. The use of gemcitabine is limited to tumors showing relapse after paclitaxel and carboplatin therapy. However, gemcitabine shows promise for use as a first-choice agent for optimized therapy in ARID1A-deficient ovarian clear cell carcinoma in the future.

CONCLUDING REMARKS

The SWI/SNF chromatin remodeling complex is composed of many subunits, and the encoding genes are frequently mutated in various cancers. Whether an inhibitor of a synthetic lethal target in cancers deficient in one gene could be effective for cancers with a deficiency in another gene, including genes encoding the subunits of the SWI/SNF chromatin remodeling complex, remains unknown. However, because the SWI/SNF chromatin remodeling
In oncogenesis by contributing to a dysregulated balance between ROS and GSH homeostasis. The clinical success rate of therapy based on biomarkers of LOF mutations in SWI/SNF chromatin remodeling genes could be improved by identifying promising drug targets using the concept of synthetic lethality. Many synthetic lethal targets for cancers with SWI/SNF chromatin remodeling complex deficiency have been identified. Inhibitors of these synthetic lethal targets have been developed, many of which are currently under clinical trials or approved for clinical use (Table 1). It is expected that these promising drugs will be approved for clinical application in cancers with SWI/SNF chromatin remodeling complex deficiency in the near future.

ACKNOWLEDGMENTS

We thank Dr Takashi Kohno for valuable guidance in writing this paper.

DISCLOSURE

The authors have no conflict of interest to declare.

ORCID

Mariko Sasaki https://orcid.org/0000-0002-2972-6775

Hideaki Ogiwara https://orcid.org/0000-0003-0860-1807

REFERENCES

1. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013;13(11):772-787.
2. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol. 2013;31(15):1904-1911.
3. Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2016;5(1):42-50.
4. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077-3080.
5. Iglehart JD, Silver DP. Synthetic lethality–a new direction in cancer-drug development. N Engl J Med. 2009;361(2):189-191.
6. McLornan DP, List A, Mufti GJ. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med. 2014;371(18):1725-1735.
7. Fang B. Development of synthetic lethality anticancer therapeutics. J Med Chem. 2014;57(19):7859-7873.
8. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110-120.
9. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921.
10. Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009;78:273-304.
11. Beck S, Bernstein BE, Campbell RM, et al. A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res. 2012;72(4):6319-6324.
12. Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113-1120.
13. Polak P, Karlic R, Koren A, et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature. 2015;518(7539):360-364.
14. Valencia AM, Kadoch C. Chromatin regulatory mechanisms and therapeutic opportunities in cancer. Nat Cell Biol. 2019;21(2):152-161.

15. Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592-601.

16. Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv. 2015;1(5):e1500447.

17. Mashtalir N, D’Avino AR, Michel BC, et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell. 2018;175(5):1272-1288.

18. Michel BC, D’Avino AR, Cassel SH, et al. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nat Cell Biol. 2018;20(12):1410-1420.

19. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153(1):71-85.

20. Oike T, Ogihara H, Tominaga Y, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 2013;73(17):5508-5518.

21. Hoffman GR, Rahal R, Buxton F, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A. 2014;111(8):3128-3133.

22. Wilson BG, Helming KC, Wang X, et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014;34(6):1136-1144.

23. Ehrenhofer-Wolfer K, Puchner T, Schwarz C, et al. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines. Sci Rep. 2019;9(1):11661.

24. Helming KC, Wang X, Wilson BG, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014;20(3):251-254.

25. Berns K, Caumans JJ, Hijmans EM, et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene. 2018;37(33):4611-4625.

26. Chun HE, Lim EL, Heravi-Moussavi A, et al. Genome-wide profiles of extra-cranial malignant rhabdoid tumors reveal heterogeneity and dysregulated developmental pathways. Cancer Cell. 2016;29(3):394-406.

27. Versteeg I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394(6689):203-206.

28. McBride MJ, Pulice JL, Beird HC, et al. The SS18-SSX fusion oncogene Hijacks BAF complex targeting and function to drive synovial sarcoma. Cancer Cell. 2018;33(6):1128-1141.

29. Wang X, Wang S, Troisi EC, et al. BRD9 defines a SWI/SNF sub-complex that mediates a synthetic lethal dependence on Aurora A in esophageal squamous cell carcinoma. Cell. 2016;169(4):1399-1410.

30. Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018;7:e41305.

31. Schick S, Rendeiro AF, Runggatscher K, et al. Systematic characterization of BAF mutations provides insights into intra-complex synthetic lethalties in human cancers. Nat Genet. 2019;51(9):1399-1410.

32. Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18(4):316-328.

33. Poynter ST, Kadoch C. Polycomb and trithorax opposition in development and disease. Wiley Interdiscip Rev Dev Biol. 2016;5(6):659-688.

34. Bitler BG, Aird KM, Garipov A, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231-238.

35. Kim KH, Kim W, Howard TP, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015;21(12):1491-1496.

36. Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110(19):7922-7927.

37. Wang X, Lee RS, Alver BH, et al. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet. 2017;49(2):289-295.

38. Nakayama RT, Pulice JL, Valencia AM, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet. 2017;49(11):1613-1623.

39. Iturriaga A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649-659.

40. Bitler BG, Wu S, Park PH, et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol. 2017;19(8):962-973.

41. Shen J, Peng Y, Wei L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5(7):752-767.

42. Dykhuizen EC, Hargreaves DC, Miller EL, et al. BAF complexes facilitate decatenation of DNA by topoisomerase Ilalpha. Nature. 2013;497(7451):624-627.

43. Williamson CT, Miller R, Pemberton HN, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837.

44. Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.

45. Xue Y, Meehan B, Macdonald E, et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nat Commun. 2019;10(1):558.

46. Xue Y, Meehan B, Fu Z, et al. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat Commun. 2019:10(1):557.

47. Wu C, Lyu J, Yang EJ, Liu Y, Zhang B, Shim JS. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat Commun. 2018;9(1):3212.

48. Deribe YL, Sun Y, Terranova C, et al. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med. 2018;24(10):1627.

49. Ogiwara H, Takahashi K, Sasaki M, et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient colorectal cancer cells. Cancer Cell. 2019;35(2):177-190.

50. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.

51. Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.

52. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707-723.

53. Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.

54. Kuroda T, Ogihara H, Sasaki M, et al. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Gynecol Oncol. 2019.

55. Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376(19):1835-1848.

56. Guan B, Mao TL, Panaganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35(5):625-632.
57. Oberley LW. Free radicals and diabetes. *Free Radic Biol Med.* 1988;5(2):113-124.

58. Ranjan P, Anathy V, Burch PM, Weirather K, Lambeth JD, Heintz NH. Redox-dependent expression of cyclin D1 and cell proliferation by Nox1 in mouse lung epithelial cells. *Antioxid Redox Signal.* 2006;8(9-10):1447-1459.

59. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. *J Cell Physiol.* 2002;192(1):1-15.

60. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. *Nat Rev Drug Discov.* 2013;12(12):931-947.

---

**How to cite this article:** Sasaki M, Ogiwara H. Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex-deficient cancers. *Cancer Sci.* 2020;111:774–782. [https://doi.org/10.1111/cas.14311](https://doi.org/10.1111/cas.14311)